Jill E Wood

USPTO Granted Patents = 23 (Patent Applications = 9)

EPO Patents = 7 (Patent Applications = 2)

Average Co-Inventor Count = 9.5

ph-index = 13

Forward Citations = 445(Granted Patents)

Location History:

Hamden, CT (US) (1998 - 2011)
North Haven, CT (US) (2004 - 2014)
Ft. Collins, CO (US) (2011 - 2014)
Fort Collins, CO (US) (2013 - 2018)

Company Filing History:

9 out of 70

Bayer Pharmaceuticals Corporation

Bayer Intellectual Property Gmbh

patents

5. 1 out of 832,680

Other

patents

Years Active: 1998-2018

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. RE46856 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2018-05-21),

2. 8859572 - Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis (2014-10-14),

3. 8841330 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors (2014-09-23),

4. 8466283 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2013-06-18),

5. 8124630 - ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors (2012-02-28),

6. 7928239 - Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas (2011-04-19),

7. 7897623 - ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors (2011-03-01),

8. 7625915 - Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas (2009-12-01),

9. 7528255 - Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors (2009-05-05),

10. 7517880 - Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas (2009-04-14),

11. 7371763 - Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas (2008-05-13),

12. 7351834 - ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors (2008-04-01),

13. 7329670 - Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas (2008-02-12),

14. 7235576 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors (2007-06-26),

15. 7109196 - 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders (2006-09-19),

Title: Innovations by Jill E. Wood in Treating Hyper-Proliferative Disorders

Introduction

Jill E. Wood, located in Hamden, CT, is an accomplished inventor known for her significant contributions to the field of pharmaceuticals. With an impressive portfolio of 23 patents, she has focused her efforts on developing novel treatments for hyper-proliferative disorders and diseases associated with angiogenesis.

Latest Patents

Among her most recent patents are the "Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis." This invention introduces new compounds that inhibit phosphatidylinositol-3-kinase (PI3K) activity, which is essential in treating various related diseases. Another notable patent is for "Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis." Like her previous patent, it focuses on compounds that demonstrate effectiveness in PI3K inhibition and are instrumental in treating hyper-proliferative and/or angiogenesis-mediated disorders.

Career Highlights

Jill E. Wood has had a remarkable career, having worked with notable companies such as Bayer Pharmaceuticals Corporation and Bayer Healthcare LLC. Her experience in these organizations has contributed to her expertise in pharmaceutical innovation, particularly in developing therapeutic agents.

Collaborations

Throughout her career, Jill has collaborated with distinguished colleagues, including William Johnston Scott and Jacques P. Dumas. This collaboration has likely fostered a rich exchange of ideas and innovations that further her impactful work in the pharmaceutical sector.

Conclusion

Jill E. Wood exemplifies dedication and innovation in the realm of pharmaceuticals. Her extensive patent portfolio and partnerships with reputable companies and colleagues highlight her commitment to advancing treatments for critical health issues related to hyper-proliferative disorders and angiogenesis. Through her inventions, she continues to make meaningful contributions to medical science.

This text is generated by artificial intelligence and may not be accurate.